Sonoma Pharmaceuticals (SNOA) Other financing activities (2011 - 2025)

Sonoma Pharmaceuticals' Other financing activities history runs 13 years deep, the most recent figure standing at $21000.0 for Q3 2025.

• On a quarterly basis, Other financing activities fell 19.23% year-over-year to $21000.0 in Q3 2025; TTM through Mar 2026 was $44000.0, a 46.34% decrease from a year earlier, with the FY2026 full-year figure at $44000.0, down 46.34% from the prior year.
• Other financing activities eased to $21000.0 in Q3 2025 per SNOA's latest filing, from $23000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $2.3 million in Q1 2021 and bottomed at $7000.0 in Q2 2024.
• The 3-year median for Other financing activities is $26000.0 (2024), against an average of $381857.1.
• Across the five-year window, Other financing activities soared 4762.0% in 2021 and slipped 19.23% in 2025, its largest moves.
• Year by year, Other financing activities stood at $216000.0 in 2021, then tumbled by 87.96% to $26000.0 in 2024, then declined by 19.23% to $21000.0 in 2025.
• Per Business Quant, the three latest SNOA Other financing activities figures stand at $21000.0 (Q3 2025), $23000.0 (Q2 2025), and $49000.0 (Q1 2025).